Andrew Schwab, Director at CAMP4 Therapeutics Corporation, holds 5.28M shares in CAMP4 Therapeutics Corporation (Ticker: CAMP), holds 9.31M shares in Skye Bioscience (Ticker: SKYE), holds 960.38K shares in Enliven Therapeutics (Ticker: ELVN). Most recently, Andrew Schwab Sold ― shares of CAMP4 Therapeutics Corporation on Aug 31, 2026 for an estimated value of $1.62M.
Andrew Schwab latest transaction was an Informative Sell of $1.62M.
What was Andrew Schwab's most profitable transaction?
Andrew Schwab’s most profitable transaction was an Informative Sell of SKYE stock on August 22, 2025. The return on the trade was 91.40%.
What is Andrew Schwab's role in CAMP4 Therapeutics Corporation?
Andrew Schwab's role in CAMP4 Therapeutics Corporation is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.